
Conference Coverage
about 18 hours ago
AHA 2026: Pharmacists at the Center of Cardiometabolic Careabout 20 hours ago
How Pharmacists Can Support Adherence to Oral PCSK9 Therapyabout 21 hours ago
From Recognition to Prior Authorization: ATTR-CM Diagnosis GapsLatest News

AHA 2026: Pharmacists at the Center of Cardiometabolic Care

FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC

How Pharmacists Can Support Adherence to Oral PCSK9 Therapy

ASRA Safety Award Highlights Medication Preparation in Interventional Pain Care

Pneumococcal Vaccines Show Moderate Immunogenicity, Strong Safety in Children With Cancer
Shorts










All News

Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.

No new vouchers have been awarded since former FDA Commissioner Marty Makary left the agency in May, although HHS maintains the pilot is ongoing.

Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.

OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.

Nicole Albanese, PharmD, explains how a structured testing schedule and simple notes help patients bring useful glucose data to their care team.

Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.

About 89% of Americans live within 5 miles of a pharmacy, but proximity says little about whether they can afford their medications or get real counseling.

ASRA’s cancer pain programming highlights opportunities for pharmacists to individualize opioid therapy, improve medication transitions, and connect patients with evidence-based complementary care.

The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.

Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.

The once-daily oral CSF-1R inhibitor was approved based on the phase 3 MANEUVER trial, which showed gains in tumor response, pain, and joint function.

In an interview with Pharmacy Times, Thomas Hope, MD, discusses where peptide receptor radionuclide therapy fits in neuroendocrine tumor treatment and how pharmacists can support treatment coordination and follow-up care.

SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.

On NET Cancer Day, a return visit for an over-the-counter antidiarrheal illustrates how pharmacists can identify a symptom pattern and help patients seek evaluation.

A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.

Adding the IL-15 agonist to frontline BCG improved responses in carcinoma in situ without new safety signals; full data are expected at an upcoming congress.

Getting patients vaccinated matters more than which COVID-19 vaccine they receive, says Jodi Longueil, PharmD.

The new agreement lets Hims & Hers patients obtain FDA-approved tirzepatide and orforglipron at Lilly’s self-pay prices.

The approval is supported by findings from the phase 3 OCEANIC-STROKE trial.

Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.

Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.

Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.

New warnings cover every GLP-1 RA, including semaglutide, tirzepatide, and orforglipron.





















